-$1.85 Earnings Per Share Expected for Agios Pharmaceuticals Inc (NASDAQ:AGIO) This Quarter
Equities analysts expect Agios Pharmaceuticals Inc (NASDAQ:AGIO) to announce ($1.85) earnings per share for the current fiscal quarter, according to Zacks Investment Research. Four analysts have provided estimates for Agios Pharmaceuticals’ earnings, with estimates ranging from ($1.95) to ($1.71). Agios Pharmaceuticals reported earnings of ($1.63) per share in the same quarter last year, which would indicate a negative year over year growth rate of 13.5%. The firm is expected to announce its next quarterly earnings results on Thursday, November 7th.
On average, analysts expect that Agios Pharmaceuticals will report full year earnings of ($7.12) per share for the current fiscal year, with EPS estimates ranging from ($7.42) to ($6.88). For the next year, analysts forecast that the company will post earnings of ($7.04) per share, with EPS estimates ranging from ($7.95) to ($6.62). Zacks’ earnings per share averages are a mean average based on a survey of analysts that follow Agios Pharmaceuticals.
Agios Pharmaceuticals (NASDAQ:AGIO) last announced its earnings results on Thursday, August 1st. The biopharmaceutical company reported ($1.87) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.70) by ($0.17). Agios Pharmaceuticals had a negative net margin of 383.05% and a negative return on equity of 59.89%. The company had revenue of $26.22 million for the quarter, compared to analysts’ expectations of $27.05 million. During the same period in the previous year, the firm earned ($1.19) EPS. The firm’s quarterly revenue was down 35.1% on a year-over-year basis.
Hedge funds have recently bought and sold shares of the business. Dimensional Fund Advisors LP grew its stake in Agios Pharmaceuticals by 27.5% in the 4th quarter. Dimensional Fund Advisors LP now owns 182,150 shares of the biopharmaceutical company’s stock valued at $8,399,000 after purchasing an additional 39,255 shares during the period. Geode Capital Management LLC boosted its holdings in shares of Agios Pharmaceuticals by 14.6% in the 4th quarter. Geode Capital Management LLC now owns 546,568 shares of the biopharmaceutical company’s stock worth $25,202,000 after buying an additional 69,603 shares during the last quarter. Creative Planning purchased a new position in shares of Agios Pharmaceuticals in the 1st quarter worth about $255,000. Virginia Retirement Systems ET AL bought a new position in Agios Pharmaceuticals during the first quarter valued at about $303,000. Finally, BNP Paribas Arbitrage SA grew its position in Agios Pharmaceuticals by 17.1% during the first quarter. BNP Paribas Arbitrage SA now owns 13,721 shares of the biopharmaceutical company’s stock valued at $925,000 after buying an additional 2,000 shares during the period.
NASDAQ AGIO traded up $2.32 on Friday, reaching $37.90. The company had a trading volume of 699,998 shares, compared to its average volume of 525,564. The company has a quick ratio of 5.91, a current ratio of 5.96 and a debt-to-equity ratio of 0.21. The company’s fifty day moving average is $41.07 and its 200 day moving average is $51.55. Agios Pharmaceuticals has a 52-week low of $33.17 and a 52-week high of $79.17. The stock has a market capitalization of $1.97 billion, a P/E ratio of -6.29 and a beta of 2.22.
Agios Pharmaceuticals Company Profile
Agios Pharmaceuticals, Inc is a biopharmaceutical company, which engages in the discovery and development of novel investigational medicines to treat cancer and rare genetic diseases. It focuses on diseases that are directly caused by changes in genes or chromosomes, often passed from one generation to the next.
Read More: Different Types of Derivatives
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.